• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    dry powder vancomycin compositions and associated methods. dry powder vancomycin compositions and methods for administering and preparing such compositions. a composition of the present disclosure can be administered to a subject by pulmonary administration in an amount effective to treat and/or prevent a bacterial infection in the subject. administering an effective amount of a composition of the present disclosure can be particularly useful in treating a gram-positive bacterial infection in an individual suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial airway infection and/or the individual's lungs.
    公开号:BR112013029803B1
    申请号:R112013029803-0
    申请日:2012-05-21
    公开日:2021-07-13
    发明作者:John Lord；Jaakko Taneli Jouhikainen；Herman E. Snyder；Pravin Soni；Mei-chang Kuo
    申请人:Savara, Inc；
    IPC主号:
    专利说明:

    Related Orders
    [001] This application claims priority from US Patent Application Serial No. 61/487,971, filed May 19, 2011, which is incorporated herein by reference. Background of the Invention
    [002] Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. Vancomycin is the international generic name (INN) corresponding to the compound with the following formula:

    [003] It has been proposed that vancomycin acts by inhibiting the correct synthesis of the cell wall in Gram-positive bacteria. More specifically, vancomycin is believed to prevent the incorporation of the subunits of the glycan portion - N-acetylmuramic acid (NAM) and N-cetylglucosamine (NAG) - into the peptidoglycan matrix, which constitutes the main structural component of Gram-cell walls. positive. The binding of vancomycin to the terminal D-alanyl-D-alanine portions of the NAM/NAG peptides prevents its incorporation into the peptidoglycan matrix.
    [004] Vancomycin has been given intravenously for systemic therapy as well as orally in the treatment of pseudomembranous colitis. Vancomycin has also been used off-label in the form of a nebulized aerosol for the treatment of various upper and lower respiratory tract infections. However, the use of an approved drug off-label may put the patient at risk, as safety and efficacy have not yet been studied and/or the appropriate dose has not been established. In addition, nebulization release can take up to 20 minutes, which is a significant inconvenience for patients. Currently, there is no known commercially available form of inhalable dry powder vancomycin. Invention Summary
    [005] The present description relates generally to dry powder compositions and methods for the administration and preparation of such compositions.
    [006] In one embodiment, the present description provides a composition comprising vancomycin or its pharmaceutically acceptable salt, wherein the composition is a dry powder.
    [007] In another embodiment, the present disclosure also provides a method comprising administering a dry powder composition containing vancomycin or its pharmaceutically acceptable salt to a subject via pulmonary administration.
    [008] In yet another embodiment, the present disclosure provides a method of spray drying which comprises an aqueous composition comprising vancomycin or its pharmaceutically acceptable salt, and a hydrophobic amino acid, so as to form a dry powder composition.
    [009] The features and advantages of the present invention will be evident to those skilled in the art. Although numerous changes can be made by those skilled in the art, such changes are within the spirit of the invention. Brief Description of Drawings
    [0010] Some examples of the specific embodiments of the disclosure can be understood by referring, in part, to the following description and the accompanying drawings.
    [0011] Figure 1 is a graph depicting the aerodynamic particle size distribution of a dry powder vancomycin composition (Lot SA010) as measured by the Andersen Cascade Impactor and RS01 Model 7 Single-Dose Inhaler.
    [0012] Figure 2 is a graph describing the effect of leucine content on the release efficiency of dry powder vancomycin compositions (Lots SA002, SA006, SA007, SA008 and SA009), measured through the fast-track impactor and RS01 Model 7 single-dose inhaler. The delivered dose (%) is the amount of drug in the dry powder leaving the inhaler in terms of percentage of the initial amount of drug in the dry powder present in the capsule. The fine particle fraction (%) is the amount of drug in the dry powder with an aerodynamic size of less than 5 µm as a percentage of the delivered dose. The release efficiency (%) is the amount of drug in the dry powder with an aerodynamic diameter less than 5 µm in percentage terms of the initial amount of drug in the capsule.
    [0013] Figure 3 is a laboratory-scale image of dry powder vancomycin particles (Lot SA010) obtained using a scanning electron microscope.
    [0014] Figure 4 is a graph depicting the aerodynamic particle size distribution of a dry powder vancomycin composition (Lot SA010), stored at 25 °C and 60% relative humidity (RH) for a period of up to 6 months, and measured using the Andersen Cascade Impactor and RS01 Model 7 Single-Dose Inhaler.
    [0015] Figure 5 is a graph representing the uniformity of the dose content delivered under 3 different stability conditions for a period of up to 6 months of 10 consecutive actuations through an RS01 Model 7 single dose inhaler in relation to the limits of ± 20% specification of FDA draft guidance (Lot SA010).
    [0016] Figure 6 is a graph depicting the aerodynamic particle size distribution of a dry powder vancomycin composition of the present disclosure (Lot L-11-26-1), measured from three RS01 single dose inhalers Model 7 tested at 100 L/min for 2.4 s (equivalent to 4 L) using an NGI Impactor (Next Generation Impactor).
    [0017] Figure 7 is a graph representing the uniformity of dose content delivered in ten RS01 Model 7 single dose inhalers tested at 100 L/min for 2.4 s (equivalent to 4 L) for Lot G-11 -26-1. The percentages of ±20% and ±25% represent the FDA draft guidance limits.
    [0018] Figure 8 is a graph depicting the effect of trehalose concentration on the chemical stability of a dry powder vancomycin composition of the present disclosure at 50°C for 4 weeks.
    [0019] Figure 9 is a graph depicting the comparison of two batches of dry powder vancomycin compositions containing 10% leucine. One batch contains no API or process modifications (Batch 20 SA010), the other has a purer API source, was processed under a nitrogen atmosphere, and precautions were taken to protect it from light and water content in the composition. powder was smaller (Lot G-11-026-1).
    [0020] Figure 10 is a pilot scale image of dry powder vancomycin particles (Lot 19SA01.HQ00005) obtained through a scanning electron microscope.
    [0021] Figure 11 is a graph depicting plasma concentrations as a function of time (semi-log) after a single dose administration of a dry powder vancomycin composition (Lot G-11-026-1) or intravenous administration of vancomycin (16 mg inhaled vancomycin dose, circle; 32 mg inhaled vancomycin dose, triangle; 80 mg inhaled vancomycin dose, square; 250 mg intravenous infusion over 60 min, circle with line).
    [0022] Although the present disclosure is susceptible to various modifications and alternative forms, examples of specific embodiments have been shown in the figures and are described in more detail herein. It should be understood, however, that the description of the examples of specific embodiments is not intended to limit the invention to the particular forms disclosed, but rather this disclosure covers all modifications and equivalents illustrated, in part, by the appended claims. Detailed Description of the Invention
    The present description generally relates to dry powder vancomycin compositions and the methods of administration and preparation of such compositions. In some embodiments, a composition of the present disclosure can be administered to a subject via pulmonary administration in an amount effective to treat and/or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure can be particularly useful in treating a Gram-positive bacterial infection in an individual suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection in the the individual's airways and/or lungs.
    [0024] In one embodiment, a composition of the present disclosure is a dry powder containing vancomycin or its pharmaceutically acceptable salt. As used herein, the term includes vancomycin analogues and vancomycin derivatives. As used herein, the term "dry" means that the composition has a moisture content such that the particles are easily dispersed in an inhalation device which forms an aerosol. In some embodiments, this moisture content can be less than about 10% by weight of water, less than about 7% by weight of water, less than about 5% by weight of water, or less than about 3 % by weight of water. Furthermore, as used herein, the term "powder" means a composition which is comprised of finely dispersed solid particles which are capable of being easily dispersed in an inhalation device and subsequently inhaled by an individual such that the particles reach the lungs and allow penetration into the upper and lower airways. Thus, the powder is said to be "breathable". In some embodiments, a dry powder composition of the present disclosure can have a tap density greater than about 0.4 g/cm3 greater than about 0.45 g/cm3 or greater than about 0 .5 g/cm3. While vancomycin may be used predominantly in the descriptions contained in this disclosure, it is to be understood that the present disclosure may be practiced with other glycopeptide antibiotics (e.g., vancomycin, teicoplanin, telavancin, bleomycin, ramoplanin, and decaplanin), and their derivatives and analogues, among other things, for the treatment of certain Gram-positive infections.
    [0025] In certain specific embodiments, a dry powder composition of the present disclosure comprises vancomycin, or its pharmaceutically acceptable salt, present in an amount of about 90% by weight of the composition, where the powder has a density of compaction greater than about 0.4 g/cm3 and further comprises leucine in an amount of about 10% by weight of the composition.
    [0026] In some embodiments, a dry powder composition of the present disclosure may comprise particles with an average particle size less than or equal to about 10 microns (μm) in diameter, as defined by the mass median aerodynamic diameter ( DAMM) (measured by the cascade impeller). In some embodiments, at least 95% of the particles have a DAMM less than about 10 µm. In some embodiments, the diameter can be less than or equal to about 7 µm. In other embodiments, the diameter can be less than or equal to about 5 µm. In certain specific embodiments, the diameter can be between about 0.5 µm and about 5 µm in diameter, particularly about 1 µm to about 3 µm. The dry powder compositions of the present disclosure comprising particles having an average particle size less than or equal to about 10 µm in diameter may be particularly useful for administration via an oral inhalation device.
    [0027] In other embodiments, a dry powder composition of the present disclosure may comprise particles with an average particle size greater than or equal to about 10 µm in diameter, as defined by the DAMM (measured through the cascade impactor) . In some embodiments, at least 95% of the particles have a DAMM greater than about 10 µm. In certain specific embodiments, the particle size can be between about 10 µm and about 50 µm in diameter, particularly about 20 µm to about 40 µm. The dry powder compositions of the present disclosure comprise particles having an average particle size greater than or equal to about 10 µm in diameter and can be particularly useful for nasal administration.
    [0028] In some embodiments, the particles may be hollow. In some embodiments, the particles can be porous. In some embodiments, the particles can have a spherical distribution, which can be relatively uniform. In some embodiments, the potency of vancomycin, as measured by microbial activity, is effectively unchanged when compared to the unformulated drug (i.e., about 5% of the drug).
    [0029] Vancomycin or its pharmaceutically acceptable salt, suitable for use in the present disclosure, is generally available from various commercial suppliers. Suitable examples of pharmaceutically acceptable salts of vancomycin include, but are not limited to, vancomycin hydrochloride, vancomycin sulfate, etc.
    [0030] In some embodiments, in addition to vancomycin, or its pharmaceutically acceptable salt, a composition of the present disclosure may further comprise one or more additives. An example of a suitable additive includes a hydrophobic amino acid. Such hydrophobic amino acids can include, but are not limited to, tryptophan, tyrosine, leucine, phenylalanine and trileucine. In some embodiments, it may be desirable to include a hydrophobic amino acid in the composition of the present disclosure in order to improve the physical stability and/or dispersibility of the composition in order to improve the chemical stability of vancomycin or its pharmaceutically acceptable salt, and/or alter the taste of the composition to mask the bitter taste of vancomycin and its salts, and/or alter the rate at which the composition is absorbed into the systemic circulation from the lung (e.g., augment or decrease the rate). While not intending to be bound by any particular theory, it is currently believed that the hydrophobic amino acid additive remains on the surface of the particles and protects them from moisture and light, thus increasing the stability of the formulation.
    [0031] Another example of a suitable additive includes a carbohydrate bulking agent. Such carbohydrate bulking agents can include, but are not limited to, lactose, mannitol, trehalose, raffinose, and maltodextrins. In some embodiments, it may be desirable to include a carbohydrate bulking agent in a composition of the present disclosure in order to improve the physical stability of the composition. Furthermore, in some embodiments, the carbohydrate bulking agent can also improve the chemical stability of vancomycin or its pharmaceutically acceptable salt. Other additives known to those skilled in the art can also be included.
    [0032] Generally, additives suitable for use in the compositions of the present disclosure may be included in an amount of about 50% or less by weight of the composition, 30% or less by weight of the composition, or 10% or less by weight of the composition. In other embodiments, additives suitable for use in the compositions of the present disclosure can be included in an amount of from about 10% to about 30% by weight of the composition. In other embodiments, additives suitable for use in the compositions of the present disclosure can be included in an amount of from about 10% to about 20% by weight of the composition.
    [0033] The compositions of the present disclosure may further comprise pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjustment and buffering agents and/or tonicity adjusting agents, such as, for example, sodium acetate , sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc. Leucine also has the double advantage of modifying the pH. Likewise, compositions of the present disclosure can contain pharmaceutically acceptable carriers and excipients including microspheres, microcapsules, nanoparticles or the like.
    [0034] In certain embodiments, the dry powder composition can be reconstituted and the resulting reconstituted powder can have a pH greater than 3.0, preferably greater than 3.5 and more preferably greater than 4.0.
    [0035] As mentioned above, administration of an effective amount of a dry powder vancomycin composition can be particularly useful in alleviating symptoms and/or treating individuals suffering from conditions, including but not limited to pneumonia and fibrosis. cystic with Gram-positive bacterial infections and/or colonization of the airways and/or lung parenchyma by bacteria or other pathogens sensitive to vancomycin or its derivatives. Other conditions may include, but are not limited to, bronchitis, bronchiectasis, diffuse panbronchiolitis, bronchiolitis, bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia (BOOP), pneumonia of any cause, including, but not limited to, acquired pneumonia in community, nosocomial pneumonia and ventilator-associated pneumonia (VAP). Examples of Gram-positive bacterial infections may include, but are not limited to, Streptococcus pneumoniae and Staphylococcus aureus bacterial infections, including methicillin-resistant Staphylococcus aureus.
    [0036] As will be recognized by a person skilled in the art, the effective amount necessary for the treatment of a particular condition or disease state will depend on the pathogen, the individual, the condition, the duration of treatment, the regularity of treatment, the type of vancomycin used, among other factors, but which can be easily determined by an expert. The patient can achieve a desired dosage by inhaling a suitable amount of the composition.
    [0037] A dry powder composition of the present disclosure may be administered to an individual by any means so long as the solid particles of the dry powder composition are capable of being inhaled by an individual such that the particles reach the lungs to allow for penetration into the upper and lower airways. In certain embodiments, a dry powder composition of the present disclosure can be administered to a patient by placing the dry powder into a suitable dosage container in a sufficient amount. Suitable dosing containers include those used in reservoir devices (eg, devices that contain more than one dose, where the device itself measures the dose) or devices with a factory-specified dose (eg, devices where each dose is contained in a single unit or multiple units). In one example, a suitable reservoir device may have a dosing container that fits within a suitable inhalation device to permit aerosolization of the dry powder composition by dispersing it in a gas stream to form an aerosol. Then, the aerosol thus produced is delivered from an attached mouthpiece which allows for subsequent inhalation by a patient in need of treatment. Such a dosage container includes any container that encloses the composition known in the art, such as gelatine, hydroxypropylmethylcellulose or plastic capsules with a removable portion or a portion that can be cut or perforated to permit dispersion of the dry powder composition (by For example, by means of a flow of gas directed into the container and through centrifugal force Such containers are exemplified by those shown in US Patent No. 4,227,522, issued October 14, 1980; US Patent No. 4,192. 309, issued March 11, 1980, and US Patent No. 4,105,027, issued August 8, 1978. Suitable containers also include those used in conjunction with GlaxoSmithKline's Ventolin Rotahaler brand powder inhaler or inhaler Fisons Spinhaler brand powder.Another suitable single-dose container, which provides a greater barrier against moisture, is formed from a plastic laminate with aluminum foil. Powder is filled by weight or by volume into the depression in the conformable sheet and hermetically sealed with a plastic laminated sheet covering. Such a container for use with a powder inhalation device is described in US Patent No. 4,778,054 and is used with GlaxoSmithKline's Diskhaler (US Patent Nos. 4,627,432, 4,811,731 and 5,035,237). All of these references are hereby incorporated by reference. In other embodiments, a dry powder composition of the present disclosure can be administered to a patient through a tracheal tube.
    [0038] In some embodiments, the compositions of the present disclosure can be prepared by spray drying an aqueous mixture of vancomycin or its salt and a pharmaceutically acceptable carrier, under conditions sufficient to provide an inhalable dry powder composition. In some embodiments, the dry powder composition is substantially amorphous.
    [0039] Generally speaking, spray drying is a process in which a homogeneous aqueous mixture of vancomycin or its salt and the vehicle is introduced through a nozzle (eg a two-fluid nozzle), rotating disk or a equivalent device, in a flow of hot gas to atomize the solution, thus forming fine droplets that subsequently mix in the flow of hot gas. The aqueous mixture can be a solution, suspension, paste, or the like, but it must be homogeneous to ensure an even distribution of the components in the mixture and ultimately the powder composition. Preferably the mixture is an aqueous solution. In some embodiments, the aqueous mixture can have a solids content of at least 1% by weight of water. In other embodiments, the aqueous mixture can have a solids content of at least 2% by weight of water. In other embodiments, the aqueous mixture can have a solids content of at least 4% by weight of water. The solvent, usually water, quickly evaporates from the droplets which produce a fine dry powder with particles 1 to 5 μm in diameter.
    [0040] In some embodiments, spray drying is carried out under conditions that result in a substantially amorphous powder of homogeneous constitution with a particle size that is breathable, a low moisture content, and characteristics that allow for immediate aerosolization. In some embodiments, the particle size of the resulting powder is such that more than about 95% of the mass is in particles having a diameter of about 10 µm or less.
    [0041] For the spraying process, such spraying methods as rotary atomization, pressure atomization and dual fluid atomization can be used. Examples of suitable devices are disclosed in US Patent No. 6,372,258, the contents of which are incorporated herein by reference.
    [0042] Alternatively, dry powder compositions can be prepared by other processes, such as lyophilization and jet milling, as disclosed in WO 91/16038, the disclosure of which is incorporated herein by reference.
    [0043] A number of formulation and processing strategies can be useful to improve, among other things, the storage and stability properties of the dry powder vancomycin compositions of the present disclosure. In certain embodiments, the vancomycin to be used can be of a high degree of purity. In other embodiments, measures can be taken to prevent the oxidation of vancomycin. For example, the processing and packaging of the composition can be carried out under nitrogen. Also, in some embodiments, processing and packaging can be performed so as to minimize exposure to direct light. Such measures can reduce light-mediated degradation of vancomycin. In some embodiments, measures can be taken to reduce the amount of moisture in the composition. Such steps can be useful to avoid hydrolysis, deamidation and oxidation of vancomycin. As mentioned above, a carbohydrate bulking agent can be added to the composition, which can also improve chemical stability.
    [0044] Furthermore, while the dry powder vancomycin compositions of the present disclosure possess many advantageous properties, in certain embodiments, a particularly advantageous property is that the compositions may have a pharmacokinetic profile that is favorable for antibacterial efficacy. of a time-dependent bactericidal antibiotic, such as vancomycin, as it can provide a prolonged high concentration of vancomycin in the lung, and consequently increase the time during which the minimal inhibitory concentrations of the target pathogens are exceeded.
    [0045] For example, in certain embodiments, after administration of a dry powder vancomycin composition to an individual, the median amount of time required for an individual's plasma levels to reach the maximum concentration of vancomycin ( Tmax) can be greater than or equal to about 30 minutes, greater than or equal to about one hour, or less than or equal to about six hours. In some embodiments, the Tmax can be between about one hour and three hours. Likewise, in certain embodiments, the median amount of time required for an individual's plasma levels to reduce by half the maximum total concentration of vancomycin (t 1/2) may be greater than six hours. In some embodiments, t 1/2 may be about eight hours.
    [0046] In certain embodiments, after administering a dry powder vancomycin composition to a subject, the mean maximum concentration of vancomycin (Cmax) in blood plasma may be within the range of about 50% to about 150 % of about nx 620 ng/mL, where n represents a factor that is multiplied and can be a value from 0.01 to 10, and when n = 1, the dose is 80 mg.
    [0047] In a particular embodiment, where vancomycin or its pharmaceutically acceptable salt is present in an amount of about 80 mg, the dry powder composition can provide a maximum mean concentration of vancomycin in blood plasma in the range of about about 50% to about 150% of about 620 ng/ml, a mean AUC 0-24h value within the range of about 50% to about 150% of about 6,250 nghr/ml, and a median Tmax value within the range of about 0.75 hours to 3 hours, measured after a single pulmonary administration. As would be recognized by one skilled in the art, for dry powder compositions containing concentrations of less than or greater than 80 mg of vancomycin, the above ranges can be adjusted directly in proportion to the dose. Thus, in certain embodiments, the present disclosure also provides compositions where vancomycin or its pharmaceutically acceptable salt is present in the dry powder composition in an amount of approximately nx 80 mg, where the dry powder composition provides: a concentration vancomycin peak mean (Cmax) in blood plasma in the range of about 50% to about 150% of about nx 620 ng/ml; an average value of AUC 0-24h within the range of about 50% to about 150% of about 6,250 n x nghr / mL; and a median Tmax value in the range of about 0.5 hour to about 6 hours, wherein the maximum concentration of vancomycin in blood plasma, the AUC value 0-24h, and the Tmax value are measured after a single pulmonary administration of the dry powder composition, where n represents a factor that is multiplied and can be a value from 0.01 to 10.
    [0048] In some embodiments, the dry powder vancomycin compositions of the present disclosure can provide a release efficiency of 40% or more. In other embodiments, the dry powder vancomycin compositions of the present disclosure can provide a release efficiency of 60% or more. The release efficiency (%) represents the amount of dry powder with an aerodynamic diameter less than 5 µm in terms of percentage of the initial amount of dry powder in the capsule. The release efficiency is the released dose (%) (i.e., the amount of dry powder leaving the inhaler as a percentage of the initial amount of dry powder present in the capsule) multiplied by the fine particle fraction (%) (i.e., the respirable amount or the amount of dry powder having a mass median aerodynamic diameter (MAMM) of 5 µm or less in percentage terms of the delivered dose).
    [0049] In some embodiments, the dry powder vancomycin compositions of the present disclosure can provide an absolute bioavailability of 40% or more. Absolute bioavailability is calculated as vancomycin AUC 0-inf after administration of the vancomycin composition divided by vancomycin AUC 0-inf after intravenous administration and adjusted by dose.
    [0050] To facilitate a better understanding of the present invention, examples of certain aspects of some embodiments are given below. In no way should the following examples limit or define the complete scope of the invention. EXAMPLE 1
    The vancomycin dry powder compositions were produced in a Buchi spray dryer at laboratory scale in high yield (75 - 95%) and in two different batch sizes (1 and 20 g) without loss of purity. These powders exhibited very high release efficiency and consistency across batches.
    [0052] The complete aerodynamic particle size distribution of the 20 g batch is represented in Figure 1, which shows that the vast majority of the particle size distribution is less than 5 µm and that a significant percentage (approximately 59%) is within the ultrafine particle fraction (3 μm) predictive for deep pulmonary delivery.
    [0053] Initial studies have shown that the uniformity of the released dose content of vancomycin powders easily meets the FDA draft guidance specifications for the uniformity of the released dose content. This has been one of the biggest challenges faced by the pulmonary delivery drug industry in the last 10 years. The specifications state that no more than 1 in 10 actuations must be outside ± 20% of the package insert/label indication without actuation outside ± 25% of the package insert/label indication.
    [0054] In some embodiments, the release efficiency of dry powder vancomycin compositions can be improved by adding small amounts of leucine (Figure 2). The addition of leucine to vancomycin powders significantly reduces the water content of the powder and the mass median aerodynamic diameter. Furthermore, the addition of leucine results in powders with physiologically acceptable pH values. See Table 1 below to see the effect of leucine concentration on water content in the powder, particle size and reconstituted pH.

    [0055] Protocol for preparing an example of a dry powder vancomycin composition Solution preparation
    [0056] An example batch formula is included in Table 2. The target mass of leucine is weighed into a beaker. The required mass of deionized water is added and mixed using a magnetic stir bar. Vancomycin hydrochloride is then added and the solution is stirred for 1.0 to 1.5 hours until it is visibly clear. The feedstock solution is prepared immediately before spray drying. The concentration of the solution is about 4% w/w total dissolved solids. TABLE 2 Composition formula for a nominal 90% vancomycin HCl, 10% of the leucine formulation (Lot SA010)
    Processing Procedure
    [0057] A benchtop spray drying system (model Buchi 191) with high efficiency cyclone is used to generate and collect the powder. For batch sizes of 19 g, dust is most conveniently recovered from the process stream via 4 dust collection events by the cyclone. The equilibrium of the drying condition is established with deionized water. When stable operation is achieved, the inlet nozzle is shifted to the stock solution. The solution is fed into the dryer until one-quarter of the solution has been used, then the nozzle is moved back into the water for approximately 5 minutes to clean the system. The dryer is then momentarily turned off to allow manifold change, restarted immediately and filled with water before the feed solution returns.
    [0058] The odor collector is quickly capped on removal to minimize exposure to ambient moisture. Each collector is then transferred to the individual glass sample vials inside a dry, low moisture glove box and the complete set of vials packaged in an aluminum bag with desiccant and heat-sealed.
    [0059] Figure 3 represents a scanning electron microscope (SEM) image of a vancomycin-leucine powder formulation from batch SA010. Stability of dry powder vancomycin compositions
    [0060] The results of a six-month stability study carried out on batch SA010 show that the aerosol particle size distribution does not change with time (Figure 4). Likewise, the released dose does not change and remains within the limits of ± 20% of the FDA draft guidance mean (Figure 5). Chemical stability from this initial study predicts that the composition would require refrigerated storage. EXAMPLE 2
    [0061] As mentioned above, in some embodiments, the dry powder vancomycin compositions of the present disclosure can be prepared using spray drying methods. Such methods have proven to be very efficient and exhibit excellent consistency across multiple batches.
    [0062] Table 3 below shows the yield, primary particle size and water content data for batch sizes ranging from 25 to 100 g, which were prepared using spray drying methods. X10, X50 and X90 represent the particle mass diameter at which 10%, 50% and 90% of the distribution is smaller, respectively. ND = not determined.
    [0063] In addition, the complete aerodynamic particle size distribution for batch G-11-26-1 is included in Figure 6 and shows that the vast majority of the particle size distribution is less than 5 µm (85%) and that a significant percentage (approximately 70%) is within the ultrafine particle fraction (< 3 μm) predictive for deep pulmonary delivery.


    [0064] Figure 7 shows that the dose content uniformity released for batch G-11-26-1 meets the FDA draft guidance specifications for aerosol dose content uniformity (ie, no more than 1 of the 10 actuations must be outside ± 20% of the indication of the package insert/label and without actuation outside ± 25% of the indication of the package insert/label). Stability
    [0065] A summary of the six-month stability study for batch G-11-026-1 is included in Table 4.
    EXAMPLE 3
    [0066] A carbohydrate bulking agent was included in a vancomycin-leucine formulation. The chemical stability of this formulation was studied at 50°C for 4 weeks. Figure 8 shows that the addition of a carbohydrate bulking agent (e.g., trehalose) can improve the chemical stability of dry powder vancomycin compositions of the present disclosure.
    Two lots of a vancomycin composition containing 10% leucine were compared. One of the batches had no process modification (Lot SA010) and the other was processed in a nitrogen atmosphere, protected from light, and protected from moisture (Lot G11-026-1). As shown in Figure 9, these modifications significantly retard vancomycin degradation. In fact, extrapolation of the data suggests that the composition is stable at room temperature for at least 2 years. EXAMPLE 4
    [0068] The powder production process was successfully scaled/extended from laboratory scale equipment to pilot scale equipment. The process can produce up to 1,000 g of powder per day with a high yield (75%) and without loss of purity.
    [0069] Figure 10 shows an SEM image of particles from a 1000 g batch (Batch 19SA01.HQ00005) manufactured in the Niro Mobile Minor "2000" spray dryer.
    [0070] Table 5 below shows the powder test data from two staggered batches. Table 6 shows the test results of the corresponding final product for Lot 19SA01.HQ00002.

    EXAMPLE 5
    After a single administration of a dry powder vancomycin composition (Lot G-11-062-1) to eighteen healthy volunteers, a slow absorption phase followed by an elimination phase was observed. The main pharmacokinetic parameters after administration of a single dose of the inhaled vancomycin and intravenous vancomycin composition are shown in Table 7. The corresponding means of the 24-hour plasma concentration curves are shown in Figure 11. The AUC (0 -t) refers to the area under the plasma concentration curve - time to the last measurable time point (24 h) which is calculated by the linear trapezoidal rule. AUC (0-inf) refers to the area under the concentration-time curve to infinity. Cmax refers to the maximum concentration of vancomycin in blood plasma, and Tmax refers to the amount of time required to reach maximum levels of vancomycin in blood plasma, et 1/2a refers to the associated elimination half-life with the terminal slope (Kel) of the semi-logarithmic drug concentration-time curve, calculated as 0.693/Kel.

    [0072] The median Tmax value was greater than one hour at all doses, suggesting a slow absorption of vancomycin from the lungs. There was a slight trend towards a lower Tmax with increasing doses (16 mg: 2 h (range 1 - 3 h), 32 mg: 1.5 h (range 1 - 3 h), 80 mg: 1.25 h (range of 1 - 2 h.) The observed Tmax values were considerably higher than expected based on previously published results with inhaled antibiotic powder (TOBI Podhaler prescribing information, the Tmax of 1 h, at all doses tested , ranges from 28 mg to 112 mg.) Vancomycin Cmax was closely well proportional to the dose between 16 mg and 80 mg (R > 0.95). the different inhaled vancomycin doses (R > 0.95) The absolute bioavailability of vancomycin after administration of the vancomycin composition, based on the results of these individuals, within each group that received both the vancomycin composition and the infusion IV, was on average 49% ± 8% (calculated as AUC (0-inf) of vancomycin after administration of the vancomycin composition divided by the AUC (0-inf) of vancomycin after intravenous administration and adjusted by dose).
    [0073] The t 1/2 with the different vancomycin dose levels was very consistent, approximately 8 h, and one greater than the t 1/2 observed after intravenous infusion. The apparent prolongation of t 1/2 suggests prolonged pulmonary absorption that continues to release vancomycin into the systemic circulation during the elimination phase of the concentration curve.
    [0074] This pharmacokinetic profile is very favorable for the antibacterial efficacy of a time-dependent bactericidal antibiotic (and concentration independent at concentrations greater than about 1 μg/mL), such as vancomycin, in that it provides an elevated and longer-lasting concentration of vancomycin in the lung, which consequently increases the time during which the minimal inhibitory concentrations of the target pathogens are exceeded.
    [0075] Therefore, the present invention is well adapted to achieve the aforementioned purposes and advantages, as well as those that are inherent to it. The particular embodiments described above are illustrative only, as the present invention may be modified and practiced in a number of different, but equivalent ways to those skilled in the art, having the benefit of the present teachings. In addition, there are no limitations on the construction or design details presented herein, except as described in the claims below. It is, therefore, evident that the particular illustrative embodiments described above may be altered or modified and all such variations are contemplated within the scope and spirit of the present invention. While compositions and methods are described in terms of "comprising", "containing", or "including" various components or steps, compositions and methods may also "consist essentially of" or "consist of" the various components and steps. All numbers and ranges revealed above may vary by a certain amount. Whenever a numerical range is disclosed, with a lower limit and an upper limit, any number and any included range that falls within the range are specifically disclosed. In particular, at each range of values (of the form, "from about a to about b", or, equivalently, "from about aab", or, equivalently, "from about a - b") described here is to be understood that each number and range included should be established within the wider range of values. Furthermore, the terms in the claims have their common and ordinary meaning, unless expressly and clearly defined by the patent holder. Furthermore, the indefinite articles "a" or "an" as used in the claims are defined herein to mean one or more than one of the element introduced. If there is any conflict in the uses of a word or term in this specification and one or more patents or other documents that may be incorporated herein by reference, definitions that are consistent with this specification shall be adopted.
    权利要求:
    Claims (12)
    [0001]
    1. Composition, CHARACTERIZED by the fact that it comprises vancomycin or a pharmaceutically acceptable salt thereof, and leucine, wherein vancomycin or its pharmaceutically acceptable salt is present in an amount of 75% to 95% by weight of the composition, wherein leucine is present in an amount of 5% to 20% by weight of the composition, where the composition is a dry powder, and where the dry powder is amorphous.
    [0002]
    2. Composition according to claim 1, CHARACTERIZED by the fact that the pharmaceutically acceptable salt comprises vancomycin hydrochloride.
    [0003]
    3. Composition according to claim 1, CHARACTERIZED by the fact that leucine is present in an amount of 10% by weight of the composition.
    [0004]
    4. Composition according to claim 1, characterized in that it further comprises a carbohydrate bulking agent, wherein the amount of carbohydrate bulking agent is less than 10% by weight of the composition.
    [0005]
    5. Composition according to claim 4, CHARACTERIZED by the fact that the carbohydrate bulking agent is selected from the group consisting of: lactose, trehalose, raffinose, and a maltodextrin.
    [0006]
    6. Composition, according to claim 4, CHARACTERIZED by the fact that the carbohydrate bulking agent is trehalose.
    [0007]
    7. Composition according to claim 1, CHARACTERIZED by the fact that the dry powder comprises particles having a mass median aerodynamic diameter less than or equal to 10 μm.
    [0008]
    8. Composition according to claim 7, CHARACTERIZED by the fact that 95% to 100% of the particles have a mass median aerodynamic diameter less than 7 μm.
    [0009]
    9. Composition according to claim 1, CHARACTERIZED by the fact that the dry powder comprises particles having a mass median aerodynamic diameter of 0.5 μm to 5 μm.
    [0010]
    10. Composition according to claim 1, CHARACTERIZED by the fact that the dry powder is encapsulated in a capsule.
    [0011]
    11. Composition according to claim 10, CHARACTERIZED by the fact that the capsule comprises hydroxypropyl cellulose.
    [0012]
    12. Composition, according to claim 1, CHARACTERIZED by the fact that vancomycin or its pharmaceutically acceptable salt is present in an amount of 90% by weight of the composition, and that leucine is present in an amount of 10% in composition weight.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112013029803B1|2021-07-13|DRY POWDER VANCOMICINE COMPOSITIONS
    US7473433B2|2009-01-06|Pulmonary delivery of polyene antifungal agents
    Fiegel et al.2008|Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin
    ES2880271T3|2021-11-24|Ultra low density lung powders
    US10561608B2|2020-02-18|Dry powder Vancomycin compositions and associated methods
    JP2008503586A|2008-02-07|Compositions, methods and systems comprising amphotericin B
    BRPI0709872A2|2011-07-26|drug microparticles
    US8846607B2|2014-09-30|Particles for treatment of pulmonary infection
    PT1594500E|2010-12-17|Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
    WO2013104892A1|2013-07-18|Application of high dose compounds via inhalation
    WO2009050726A2|2009-04-23|Compositions and methods for improved delivery of bupropion
    HU0104928A2|2002-04-29|Pharmaceutical compositions comprising micronised colistin sulphomethate natrium, process for their preparation and their use
    NZ618002B2|2015-06-30|Dry powder vancomycin compositions and associated methods
    ES2352729T3|2011-02-22|TREATMENT OF BACTERIAL DISEASES OF RESPIRATORY BODIES THROUGH LOCAL ADMINISTRATION OF FLUOROQUINOLONES.
    Auriemma et al.2013|Gentamicin and particle engineering: from an old molecule to innovative drug delivery systems
    KR20180052566A|2018-05-18|Tripentad powder for pulmonary delivery
    JPWO2017022814A1|2018-05-31|Nebulizer composition
    同族专利:
    公开号 | 公开日
    EP2709646A1|2014-03-26|
    JP6012716B2|2016-10-25|
    CA2981038A1|2012-11-22|
    BR112013029803A2|2017-01-17|
    MX346244B|2017-03-13|
    KR20140032450A|2014-03-14|
    CN103717231A|2014-04-09|
    CA2836643C|2017-11-14|
    NZ618002A|2015-03-27|
    IL229506A|2019-07-31|
    KR101763195B1|2017-07-31|
    MX2013013503A|2014-05-12|
    CA2836643A1|2012-11-22|
    SG195038A1|2013-12-30|
    CA2981038C|2018-09-25|
    EP2709646A4|2015-05-13|
    JP2014515356A|2014-06-30|
    IL229506D0|2014-01-30|
    AU2012254999B2|2016-02-11|
    WO2012159103A1|2012-11-22|
    NZ704819A|2016-05-27|
    CN103717231B|2016-08-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NZ205892A|1982-10-08|1987-07-31|Glaxo Group Ltd|Inhalation device; including a penetrating member and rotatable indexing means|
    US4778054A|1982-10-08|1988-10-18|Glaxo Group Limited|Pack for administering medicaments to patients|
    DK163640C|1985-07-30|1992-08-17|Glaxo Group Ltd|DEVICE FOR ADMINISTRATING MEDICINES|
    JPH03193735A|1989-12-22|1991-08-23|Shionogi & Co Ltd|Stabilized composition of glycopeptide-based antibiotic|
    JPH05963A|1990-04-13|1993-01-08|Toray Ind Inc|Polypeptide composition|
    US6582728B1|1992-07-08|2003-06-24|Inhale Therapeutic Systems, Inc.|Spray drying of macromolecules to produce inhaleable dry powders|
    US6051256A|1994-03-07|2000-04-18|Inhale Therapeutic Systems|Dispersible macromolecule compositions and methods for their preparation and use|
    JP4142149B2|1997-07-10|2008-08-27|明治製菓株式会社|Vancomycin lyophilized formulation|
    US6586008B1|1999-08-25|2003-07-01|Advanced Inhalation Research, Inc.|Use of simple amino acids to form porous particles during spray drying|
    EP1666028B1|1999-10-29|2010-03-24|Novartis AG|Dry powder compositions having improved dispersivity|
    JP4837892B2|2001-11-01|2011-12-14|ネクターセラピューティクス|Method for producing powder batch|
    DE10358387A1|2003-12-13|2005-07-07|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Powder containing low molecular weight dextran and process for their preparation|
    FR2872044B1|2004-06-28|2007-06-29|Flamel Technologies Sa|PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM|
    EP2050437A1|2007-10-15|2009-04-22|Laboratoires SMB|Improved pharmaceutical dry powder compositions for inhalation.|
    NZ719761A|2008-10-07|2017-11-24|Raptor Pharmaceuticals Inc|Aerosol fluoroquinolone formulations for improved pharmacokinetics|
    CN108434126B|2009-03-26|2021-11-19|普马特里克斯营业公司|Dry powder formulations and methods for treating pulmonary diseases|
    WO2010111641A2|2009-03-26|2010-09-30|Pulmatrix, Inc.|Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis|WO2007067520A2|2005-12-08|2007-06-14|Transave, Inc.|Lipid-based compositions of antiinfectives for treating pulmonary infections|
    US9119783B2|2007-05-07|2015-09-01|Insmed Incorporated|Method of treating pulmonary disorders with liposomal amikacin formulations|
    AU2013352259B2|2012-11-29|2018-06-14|Insmed Incorporated|Stabilized vancomycin formulations|
    WO2014110200A1|2013-01-10|2014-07-17|Zisman Lawrence S|Non-selective kinase inhibitors|
    CN104043104B|2013-03-15|2018-07-10|浙江创新生物有限公司|The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin|
    US9925184B2|2013-10-11|2018-03-27|Pulmokine, Inc.|Spray-dry formulations|
    WO2015128495A1|2014-02-28|2015-09-03|Algipharma As|Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function|
    JP6552528B2|2014-03-14|2019-07-31|キューティスファーマ インコーポレーテッドＣｕｔｉｓｐｈａｒｍａ， Ｉｎｃ．|Compositions and methods for vancomycin oral liquid|
    ME03536B|2014-05-15|2020-04-20|Insmed Inc|Methods for treating pulmonary non-tuberculous mycobacterial infections|
    RS59851B1|2014-11-06|2020-02-28|Xellia Pharmaceuticals Aps|Glycopeptide compositions|
    CN107106585B|2015-02-06|2021-01-01|杭州美南医药科技有限公司|Aqueous vancomycin solution preparation|
    BR112019008622A2|2016-10-27|2019-07-09|Pulmokine Inc|method to treat a condition|
    CN106963939A|2017-03-22|2017-07-21|永信药品工业（昆山）股份有限公司|Vancomycin hydrochloride pharmaceutical composition and preparation method thereof|
    US20200115412A1|2018-10-15|2020-04-16|Savara Inc.|Separation of vancomycin and its degradation products|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-03-19| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
    2019-07-02| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|
    2021-01-26| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|
    2021-06-01| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-07-13| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2012, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US201161487971P| true| 2011-05-19|2011-05-19|
    US61/487,971|2011-05-19|
    PCT/US2012/038775|WO2012159103A1|2011-05-19|2012-05-21|Dry powder vancomycin compositions and associated methods|
    [返回顶部]